 OSLO, Norway--BUSINESS WIRE--- ULTI DOVACC--Ultimovacs ASA Ultimovacs, ticker ULTI, today announced its participation in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology Clinical Trial Unit NSGO-CTU, the European Network of Gynaecological Oncological Trial Groups ENGOT and AstraZeneca, to conduct a randomized Phase II clinical trial to evaluate Ultimovacs proprietary universal cancer vaccine, UV1, in combination with AstraZenecas durvalumab and olaparib 